Teva Capex To Revenue vs Ebit Per Revenue Analysis

TEVA Stock

USD 17.12 0.04 0.23%

Teva Pharma financial indicator trend analysis is much more than just breaking down Teva Pharma Industries prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Teva Pharma Industries is a good investment. Please check the relationship between Teva Pharma Capex To Revenue and its Ebit Per Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

Capex To Revenue vs Ebit Per Revenue

Capex To Revenue vs Ebit Per Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Teva Pharma Industries Capex To Revenue account and Ebit Per Revenue. At this time, the significance of the direction appears to have no relationship.

The correlation between Teva Pharma's Capex To Revenue and Ebit Per Revenue is 0.05. Overlapping area represents the amount of variation of Capex To Revenue that can explain the historical movement of Ebit Per Revenue in the same time period over historical financial statements of Teva Pharma Industries, assuming nothing else is changed. The correlation between historical values of Teva Pharma's Capex To Revenue and Ebit Per Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Revenue of Teva Pharma Industries are associated (or correlated) with its Ebit Per Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit Per Revenue has no effect on the direction of Capex To Revenue i.e., Teva Pharma's Capex To Revenue and Ebit Per Revenue go up and down completely randomly.

Correlation Coefficient

0.05

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Ebit Per Revenue

Most indicators from Teva Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Teva Pharma Industries current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

At present, Teva Pharma's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 40.5 B, whereas Tax Provision is forecasted to decline to (7.3 M).

	2021	2023	2024 (projected)
Interest Expense	1.1B	1.0B	1.1B
Depreciation And Amortization	1.3B	1.2B	1.2B

Interest Expense Depreciation And Amortization

Teva Pharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Short Term Investments	Common Stock	Other Liab
Total Assets		0.76	0.26	0.96	0.71	0.91	0.73	0.27	0.02	0.99	0.52	0.02	0.93	0.62	0.74	0.81	0.19	0.4	0.83	0.85	0.71	0.92	0.13	-0.14	-0.67	0.57
Short Long Term Debt Total	0.76		0.45	0.71	0.14	0.66	0.99	-0.38	-0.14	0.8	-0.04	-0.14	0.6	0.73	1.0	0.49	0.07	0.8	0.98	0.43	0.56	0.82	-0.4	0.4	-0.48	0.83
Other Current Liab	0.26	0.45		0.18	0.01	0.18	0.44	-0.28	0.01	0.29	-0.14	0.01	0.05	0.38	0.49	0.07	0.63	0.53	0.46	0.07	0.24	0.22	-0.36	0.37	-0.25	0.61
Total Current Liabilities	0.96	0.71	0.18		0.66	0.96	0.67	0.23	0.06	0.93	0.55	0.06	0.95	0.7	0.68	0.9	0.29	0.41	0.79	0.9	0.79	0.85	0.18	-0.12	-0.77	0.48
Total Stockholder Equity	0.71	0.14	0.01	0.66		0.61	0.1	0.82	0.23	0.65	0.89	0.23	0.79	0.06	0.13	0.66	0.18	-0.17	0.29	0.8	0.47	0.56	0.62	-0.61	-0.57	0.08
Property Plant And Equipment Net	0.91	0.66	0.18	0.96	0.61		0.61	0.17	0.16	0.86	0.56	0.16	0.89	0.79	0.63	0.92	0.39	0.48	0.74	0.92	0.68	0.71	0.28	0.0	-0.84	0.42
Net Debt	0.73	0.99	0.44	0.67	0.1	0.61		-0.37	-0.3	0.79	-0.06	-0.3	0.58	0.67	0.98	0.46	0.01	0.73	0.95	0.35	0.57	0.82	-0.48	0.36	-0.4	0.78
Retained Earnings	0.27	-0.38	-0.28	0.23	0.82	0.17	-0.37		0.03	0.21	0.81	0.03	0.42	-0.42	-0.4	0.32	0.0	-0.7	-0.26	0.42	0.19	0.17	0.66	-0.89	-0.12	-0.43
Cash	0.02	-0.14	0.01	0.06	0.23	0.16	-0.3	0.03		-0.07	0.13	1.0	0.01	0.18	-0.1	0.08	0.3	0.24	-0.04	0.39	-0.17	-0.21	0.57	0.18	-0.38	0.15
Non Current Assets Total	0.99	0.8	0.29	0.93	0.65	0.86	0.79	0.21	-0.07		0.44	-0.07	0.89	0.59	0.79	0.74	0.12	0.42	0.86	0.76	0.68	0.95	0.02	-0.12	-0.59	0.62
Non Currrent Assets Other	0.52	-0.04	-0.14	0.55	0.89	0.56	-0.06	0.81	0.13	0.44		0.13	0.71	0.01	-0.06	0.69	0.24	-0.27	0.11	0.71	0.41	0.33	0.74	-0.61	-0.63	-0.15
Cash And Short Term Investments	0.02	-0.14	0.01	0.06	0.23	0.16	-0.3	0.03	1.0	-0.07	0.13		0.01	0.18	-0.1	0.08	0.3	0.24	-0.04	0.39	-0.17	-0.21	0.57	0.18	-0.38	0.15
Net Receivables	0.93	0.6	0.05	0.95	0.79	0.89	0.58	0.42	0.01	0.89	0.71	0.01		0.51	0.56	0.89	0.2	0.24	0.69	0.89	0.78	0.84	0.27	-0.29	-0.75	0.32
Common Stock Shares Outstanding	0.62	0.73	0.38	0.7	0.06	0.79	0.67	-0.42	0.18	0.59	0.01	0.18	0.51		0.72	0.65	0.49	0.82	0.73	0.6	0.5	0.45	-0.12	0.54	-0.7	0.55
Non Current Liabilities Total	0.74	1.0	0.49	0.68	0.13	0.63	0.98	-0.4	-0.1	0.79	-0.06	-0.1	0.56	0.72		0.46	0.07	0.82	0.98	0.41	0.5	0.8	-0.39	0.43	-0.47	0.88
Inventory	0.81	0.49	0.07	0.9	0.66	0.92	0.46	0.32	0.08	0.74	0.69	0.08	0.89	0.65	0.46		0.4	0.29	0.59	0.91	0.77	0.62	0.36	-0.13	-0.86	0.19
Other Current Assets	0.19	0.07	0.63	0.29	0.18	0.39	0.01	0.0	0.3	0.12	0.24	0.3	0.2	0.49	0.07	0.4		0.29	0.13	0.42	0.37	-0.05	0.14	0.14	-0.57	0.08
Other Stockholder Equity	0.4	0.8	0.53	0.41	-0.17	0.48	0.73	-0.7	0.24	0.42	-0.27	0.24	0.24	0.82	0.82	0.29	0.29		0.78	0.27	0.24	0.36	-0.35	0.81	-0.52	0.79
Total Liab	0.83	0.98	0.46	0.79	0.29	0.74	0.95	-0.26	-0.04	0.86	0.11	-0.04	0.69	0.73	0.98	0.59	0.13	0.78		0.56	0.6	0.85	-0.26	0.33	-0.6	0.85
Total Current Assets	0.85	0.43	0.07	0.9	0.8	0.92	0.35	0.42	0.39	0.76	0.71	0.39	0.89	0.6	0.41	0.91	0.42	0.27	0.56		0.65	0.62	0.52	-0.21	-0.85	0.27
Short Term Debt	0.71	0.56	0.24	0.79	0.47	0.68	0.57	0.19	-0.17	0.68	0.41	-0.17	0.78	0.5	0.5	0.77	0.37	0.24	0.6	0.65		0.7	-0.1	-0.19	-0.59	0.24
Intangible Assets	0.92	0.82	0.22	0.85	0.56	0.71	0.82	0.17	-0.21	0.95	0.33	-0.21	0.84	0.45	0.8	0.62	-0.05	0.36	0.85	0.62	0.7		-0.16	-0.16	-0.43	0.61
Accounts Payable	0.13	-0.4	-0.36	0.18	0.62	0.28	-0.48	0.66	0.57	0.02	0.74	0.57	0.27	-0.12	-0.39	0.36	0.14	-0.35	-0.26	0.52	-0.1	-0.16		-0.45	-0.41	-0.32
Short Term Investments	-0.14	0.4	0.37	-0.12	-0.61	0.0	0.36	-0.89	0.18	-0.12	-0.61	0.18	-0.29	0.54	0.43	-0.13	0.14	0.81	0.33	-0.21	-0.19	-0.16	-0.45		-0.14	0.45
Common Stock	-0.67	-0.48	-0.25	-0.77	-0.57	-0.84	-0.4	-0.12	-0.38	-0.59	-0.63	-0.38	-0.75	-0.7	-0.47	-0.86	-0.57	-0.52	-0.6	-0.85	-0.59	-0.43	-0.41	-0.14		-0.36
Other Liab	0.57	0.83	0.61	0.48	0.08	0.42	0.78	-0.43	0.15	0.62	-0.15	0.15	0.32	0.55	0.88	0.19	0.08	0.79	0.85	0.27	0.24	0.61	-0.32	0.45	-0.36

Click cells to compare fundamentals

Teva Pharma Account Relationship Matchups

Teva Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	57.5B	50.6B	47.7B	44.0B	43.5B	26.4B
Short Long Term Debt Total	27.3B	26.4B	23.5B	21.6B	20.2B	21.2B
Other Current Liab	890M	8.1B	7.8B	7.4B	7.9B	8.3B
Total Current Liabilities	13.7B	13.2B	11.0B	11.5B	12.2B	6.5B
Total Stockholder Equity	14.0B	10.0B	10.3B	7.9B	7.5B	9.9B
Property Plant And Equipment Net	7.0B	6.9B	6.5B	6.2B	6.1B	3.2B
Net Debt	25.4B	24.2B	21.3B	18.8B	16.9B	17.8B
Retained Earnings	(7.0B)	(10.9B)	(10.5B)	(12.9B)	(13.5B)	(12.9B)
Cash	2.0B	2.2B	2.2B	2.8B	3.2B	3.4B
Non Current Assets Total	44.0B	37.6B	35.1B	32.0B	31.0B	18.7B
Non Currrent Assets Other	591M	538M	515M	441M	463M	594.6M
Cash And Short Term Investments	2.0B	2.2B	2.2B	2.8B	3.2B	3.4B
Net Receivables	5.7B	4.6B	4.5B	3.7B	3.4B	3.0B
Common Stock Shares Outstanding	1.1B	1.1B	1.1B	1.1B	1.1B	777.0M
Liabilities And Stockholders Equity	57.5B	50.6B	47.7B	44.0B	43.5B	26.4B
Non Current Liabilities Total	28.7B	26.4B	25.4B	23.8B	23.1B	24.3B
Inventory	4.4B	4.4B	3.8B	3.8B	4.0B	2.4B
Other Current Assets	434M	1.8B	2.1B	1.7B	1.8B	1.1B
Other Stockholder Equity	23.2B	23.3B	23.4B	23.6B	23.7B	24.9B
Total Liab	42.4B	39.6B	36.4B	35.3B	35.4B	37.1B
Total Current Assets	13.5B	13.0B	12.6B	12.1B	12.5B	7.7B
Short Term Debt	2.3B	3.3B	1.5B	2.2B	1.8B	1.3B
Intangible Assets	11.2B	8.9B	7.5B	6.3B	5.4B	4.7B
Accounts Payable	1.7B	1.8B	1.7B	1.9B	2.6B	2.1B
Accumulated Other Comprehensive Income	(2.3B)	(2.4B)	(2.7B)	(2.8B)	(2.7B)	(2.6B)
Other Liab	3.7B	3.2B	3.4B	4.4B	5.1B	5.3B
Other Assets	2.1B	1.1B	1M	(1M)	1.9B	950K
Long Term Debt	24.6B	22.7B	21.6B	19.1B	18.2B	12.5B
Property Plant Equipment	6.4B	6.3B	6.0B	6.2B	7.1B	4.8B
Current Deferred Revenue	8.7B	7.3B	7.0B	1.5B	4.9B	3.1B
Good Will	24.8B	20.6B	20.0B	17.6B	17.2B	17.7B
Property Plant And Equipment Gross	6.4B	6.9B	6.5B	6.2B	11.8B	12.4B
Short Long Term Debt	2.3B	3.2B	1.4B	2.1B	1.7B	2.6B
Net Tangible Assets	(22.1B)	(19.5B)	(17.2B)	(16.0B)	(14.4B)	(15.1B)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:

How To Invest In Teva

Details

Is Teva Stock a good investment?

Details

What is Teva Pharma's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.4

Earnings Share

(0.85)

Revenue Per Share

14.879

Quarterly Revenue Growth

0.125

Return On Assets

0.0556

The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Teva Capex To Revenue vs Ebit Per Revenue Analysis

Capex To Revenue vs Ebit Per Revenue

Capex To Revenue vs Ebit Per Revenue Correlation Analysis

Correlation Coefficient

Capex To Revenue

Ebit Per Revenue

Teva Pharma fundamental ratios Correlations

Teva Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Teva Pharma fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 1.0	Cash
Non Current Assets Total	+ 0.99	Total Assets
Net Debt	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.98	Short Long Term Debt Total
Non Current Liabilities Total	+ 0.98	Net Debt

Short Term Investments	- 0.89	Retained Earnings
Common Stock	- 0.86	Inventory
Common Stock	- 0.85	Total Current Assets
Common Stock	- 0.84	Property Plant And Equipment Net
Common Stock	- 0.77	Total Current Liabilities
Common Stock	- 0.75	Net Receivables